A Phase 1, Double-Blind, Randomized, Single Dose Escalation Safety Study of Intra-articular OP-1 in Subjects With Osteoarthritis of the Knee

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-31

Study Completion Date

2008-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to investigate the safety and tolerability of OP-1 when it is injected into the knee joint of patients who have osteoarthritis on the knee.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee

NCT01111045

Osteoarthritis of the Knee

COMPLETED PHASE2

Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee

NCT01133613

Osteoarthritis of the Knee

COMPLETED PHASE1

a Single Intraarticular Injection of PRP for Early Knee OA

NCT04027738

Knee Osteoarthritis

COMPLETED NA

Safety and Efficacy of Intra-articular Ozone Injections for Knee Osteoarthritis

NCT02833545

Osteoarthritis Knee

COMPLETED PHASE4

Cell-free Stem Cell-derived Extract Formulation for Knee Osteoarthritis

NCT04971798

Osteoarthritis, Knee

NOT_YET_RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects with OA will be recruited and informed consent obtained. During a screening period lasting 1 to 28 days, subjects will undergo medical and arthritis history, physical examination, collection of concomitant medications, KOOS (which contains the WOMAC questionnaire), SF-36 and global 100 mm VAS assessments, have samples obtained for urinalysis, hematology, chemistry, immunology and serum and plasma for future biomarker testing, ECG, bilateral knee x-rays and MRI of the index knee at selected sites. Subjects who meet all of the inclusion criteria and none of the exclusion criteria will be randomized into the first cohort of 8 subjects to receive either 1.0 mL lactose (placebo) (2 subjects) or 1.0 mL OP-1 (6 subjects) intraarticularly using ultrasound or fluoroscopy guidance in an outpatient setting on day 1. Each cohort will consist of 8 treated patients, with treatment allocation in a 3:1 active-to-lactose (placebo) ratio. After an observation period of at least one hour, subjects will be released and contacted via telephone on Day 2 to query for AEs and concomitant medications. Additional follow-up visits will be done on days 7, 14, 28, 56, 84 and 168 (weeks 1, 2, 4, 8, 12 and 24) and safety and efficacy parameters evaluated according to the Schedule of Events. When a minimum of 4 weeks have elapsed since the last patient of the current cohort has been treated, all safety data will be collected and reviewed by the Principal Investigators and the Sponsor. The safety review will be conducted to ensure the demonstrated safety profile of OP-1 is acceptable for the treated patients. Only after the current dose level has been judged to be safe will dose escalation to the next dosing cohort occur.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis of the Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intra-articular Injection of OP-1 to affected knee

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ambulatory subjects with OA of the knee with symptoms for at least 6 months and pain on the majority of days in the last 30 days. Symptoms must include knee joint pain, and may include crepitus, swelling and/or effusion of the knee. In subjects with bilateral knee OA, the more symptomatic knee is the index knee. Subjects may be taking NSAIDs, analgesics and/or undergoing physical therapy.
* Age \> 40 years
* Radiographic evidence on posteroanterior (PA) and lateral standing, flexed x-rays of at least one osteophyte.
* Subjects must be willing to abstain from other intraarticular treatments of the knee or any surgery for 12 weeks on study.
* Ability to comply with the study and give informed consent.
* Subjects must be willing to abstain from NSAIDs or analgesic medications (except for acetaminophen) for 48 hours prior to assessments, at screening, day 1 and week 4, 8, 12, and 24 visits.

Exclusion Criteria

* Concurrent medical or arthritic conditions which could interfere with evaluation of the index knee joint including fibromyalgia.
* Subject has received arthroscopic or open surgery to the index joint within 6 months of study start
* The presence of surgical hardware or other foreign body in the index joint
* Corticosteroid, hyaluronic acid or other intraarticular injection within 3 months of study start
* Use of chondroitin and/or glucosamine within 4 weeks prior to study start
* History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, lymphoma, arthritis associated with inflammatory bowel disease, sarcoidosis or amyloidosis
* Clinical signs and symptoms of active knee infection or crystal disease
* Clinically significant cardiac disease, consult study Medical Monitor
* Have an increased predisposition for the development of infections
* History of malignancy, with the exception of resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ.
* More significant pain from the back or the hip than the knee
* Skin breakdown at the knee where the injection would take place
* Planned knee replacement during the study period
* For subjects undergoing MRI, the presence of contraindications to having an MRI at the specific imaging facility.
* For subjects undergoing MRI, an estimated Glomerular Filtration Rate (eGFR) of \<45 mL/min calculated using the Cockcroft-Gault estimate for eGFR as follows:

eGFR = (140-age \[yrs\]) X weight \[kg\] / serum creatinine \[mg/dL\] X 72 (X 0.85 for women)

* For subjects undergoing MRI, known allergy to gadolinium contrast material
* Has known or clinically suspected infection with human immunodeficiency virus (HIV), hepatitis C or B viruses
* Has participated within 30 days or will participate concurrently in another investigational drug or vaccine study
* Has a history of drug or alcohol dependence in the past 3 years
* Known sensitivity to lidocaine or OP-1
* Female with reproductive capability
* Has other serious, non-malignant, significant, acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.
* Prior use of a bone morphogenetic protein.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No